ATE323485T1 - Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer - Google Patents

Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer

Info

Publication number
ATE323485T1
ATE323485T1 AT00989357T AT00989357T ATE323485T1 AT E323485 T1 ATE323485 T1 AT E323485T1 AT 00989357 T AT00989357 T AT 00989357T AT 00989357 T AT00989357 T AT 00989357T AT E323485 T1 ATE323485 T1 AT E323485T1
Authority
AT
Austria
Prior art keywords
release
cyclooxygenase
inhibitor
release rates
different release
Prior art date
Application number
AT00989357T
Other languages
English (en)
Inventor
Subhash Desai
Sreekant Nadkarni
Randy J Wald
Brincat Gary A De
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE323485T1 publication Critical patent/ATE323485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT00989357T 1999-12-22 2000-12-20 Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer ATE323485T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17173899P 1999-12-22 1999-12-22
US18160400P 2000-02-10 2000-02-10
US20227000P 2000-05-05 2000-05-05

Publications (1)

Publication Number Publication Date
ATE323485T1 true ATE323485T1 (de) 2006-05-15

Family

ID=27390015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989357T ATE323485T1 (de) 1999-12-22 2000-12-20 Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer

Country Status (25)

Country Link
US (1) US7220434B2 (de)
EP (1) EP1239857B1 (de)
JP (1) JP2003518062A (de)
KR (1) KR100717549B1 (de)
CN (1) CN1230167C (de)
AT (1) ATE323485T1 (de)
AU (1) AU780774C (de)
BR (1) BR0016705A (de)
CA (1) CA2394232C (de)
CY (1) CY1105050T1 (de)
CZ (1) CZ300745B6 (de)
DE (1) DE60027464T2 (de)
DK (1) DK1239857T3 (de)
ES (1) ES2258988T3 (de)
IL (2) IL150353A0 (de)
MX (1) MXPA02006151A (de)
MY (1) MY127898A (de)
NO (1) NO20022987L (de)
NZ (1) NZ519467A (de)
PE (1) PE20010994A1 (de)
PL (1) PL201409B1 (de)
PT (1) PT1239857E (de)
SK (1) SK9032002A3 (de)
TW (1) TWI286073B (de)
WO (1) WO2001045706A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
EA011309B1 (ru) 2000-06-13 2009-02-27 Вайет Составы для ослабления боли, содержащие целекоксиб
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
EP1322158B1 (de) * 2000-10-02 2012-08-08 USV Ltd. Metformin enthaltende pharmazeutische Zusammensetzungen mit verzögerter Wirkstofffreigabe und Verfahren zu deren Herstellung
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20030100595A1 (en) * 2001-11-13 2003-05-29 Aziz Karim Oral dosage form of a sulfonamide prodrug
AU2002357366A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Multiple-pulse extended release formulations of clindamycin
WO2003057196A1 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Drug mixture with enhanced dissolution rate
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003295846A1 (en) * 2002-11-26 2004-06-18 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
EP2339328A3 (de) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
FR2861990B1 (fr) 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
CA2589167A1 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
EA200801449A1 (ru) * 2005-12-23 2008-12-30 Лек Фармасьютиклз Д.Д. Разрывные гранулы
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
KR100762847B1 (ko) * 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
US20100233272A1 (en) * 2007-11-15 2010-09-16 Leah Elizabeth Appel Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US8323360B2 (en) * 2008-06-30 2012-12-04 3M Innovative Properties Company Method of crystallization
WO2010014952A2 (en) 2008-07-31 2010-02-04 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
PL387415A1 (pl) * 2009-03-06 2010-09-13 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
EP2384746A3 (de) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Orale Tablettenzusammensetzungen aus Dexlansoprazol mit dualer Freisetzung
US8563035B2 (en) * 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
CN103462920A (zh) * 2012-06-06 2013-12-25 南京亿华药业有限公司 一种口服环加氧酶-2抑制剂塞来昔布的组合物
US10413520B2 (en) 2014-01-29 2019-09-17 Crystalgenomics, Inc. Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
KR101446601B1 (ko) * 2014-01-29 2014-10-07 크리스탈지노믹스(주) 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
EP3554547A4 (de) 2016-12-14 2020-08-12 Druggability Technologies IP Holdco Limited Pharmazeutische zusammensetzung mit celekoxib
EP3768094B1 (de) 2018-03-15 2024-05-01 R.P. Scherer Technologies, LLC Enterale weichgelkapseln
WO2021124044A1 (en) 2019-12-16 2021-06-24 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase – 2 inhibitors
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
ATE223390T1 (de) * 1995-02-13 2002-09-15 Searle & Co Substituierte isoxazole zur behandlung von entzündung
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
EP0863134A1 (de) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-on zur Verwendung als Inhibitor der Cyclooxygenase-2
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
NZ513965A (en) * 1999-03-10 2004-04-30 G Method and composition for administering a cyclooxygenase-2 inhibitor
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2

Also Published As

Publication number Publication date
PL201409B1 (pl) 2009-04-30
SK9032002A3 (en) 2003-03-04
CY1105050T1 (el) 2010-03-03
CA2394232A1 (en) 2001-06-28
BR0016705A (pt) 2002-09-24
EP1239857A1 (de) 2002-09-18
TWI286073B (en) 2007-09-01
DE60027464T2 (de) 2006-08-31
CN1433309A (zh) 2003-07-30
US7220434B2 (en) 2007-05-22
US20040242640A1 (en) 2004-12-02
CA2394232C (en) 2009-06-09
CZ300745B6 (cs) 2009-07-29
JP2003518062A (ja) 2003-06-03
AU780774C (en) 2006-09-21
PE20010994A1 (es) 2001-09-21
KR100717549B1 (ko) 2007-05-11
AU780774B2 (en) 2005-04-14
CN1230167C (zh) 2005-12-07
PT1239857E (pt) 2006-07-31
KR20020072554A (ko) 2002-09-16
EP1239857B1 (de) 2006-04-19
IL150353A (en) 2008-07-08
AU2586801A (en) 2001-07-03
ES2258988T3 (es) 2006-09-16
MXPA02006151A (es) 2004-09-06
PL355715A1 (en) 2004-05-17
NO20022987D0 (no) 2002-06-20
DK1239857T3 (da) 2006-07-31
MY127898A (en) 2006-12-29
HK1055677A1 (en) 2004-01-21
NZ519467A (en) 2004-02-27
IL150353A0 (en) 2002-12-01
NO20022987L (no) 2002-08-21
WO2001045706A1 (en) 2001-06-28
DE60027464D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
DE60027464D1 (de) Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer
AP1637A (en) Celecoxib compositions.
MX9604354A (es) Nueva forma de dosis farmaceutica oral.
WO1997048391A3 (en) Methods and compositions comprising r-ibuprofen
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
BR9908438A (pt) Tabletes de desintegração rápida
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
UY26926A1 (es) Derivados de la quinolina y quinazolina
DK1280799T3 (da) Orthosubstituerede anthranilsyreamider og anvendelse heraf som lægemidler
TW200738228A (en) Neramexane modified release matrix tablet
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
ATE460157T1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
Gujral et al. An updated review on modified release tablets
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
PL368686A1 (en) Novel aminobenzoephenones
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
MXPA04004290A (es) Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
RU99127981A (ru) Способ лечения рецидивирующего фурункулеза
AR022475A1 (es) Metodo para la prevencion o reduccion de eventos cardiovasculares asociados con intervencion coronaria.
ATE337826T1 (de) Simplifizierte sarcodictyn-derivate als anti- tumor-mittel
KR100405918B1 (en) Pharmaceutical composition for treatment of cancer containing p43 protein and paclitaxel
DK1379253T3 (da) Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1239857

Country of ref document: EP